BioSpace News Archive

According to the report, the global newborn screening market was valued at ~US$ 940 Mn in 2019 and is projected to expand at a CAGR of ~11% from 2021 to 2031.

The shareholders of Spago Nanomedical AB, corporate registration number 556574-5048 are hereby summoned to the Annual General Meeting on Wednesday May 18, 2022, at 4.00 p.m. CEST in the premises of Advokatfirman Cederquist at Hovslagargatan 3 in Stockholm.

Diagnostics company SphingoTec GmbH announced the implementation of two critical care biomarkers to guide the application of a potential new drug candidate for the treatment of COVID-19 patients.

InventisBio Co., Ltd., a clinical-stage biotech company based in Shanghai, China has published the clinical data of their oral KRAS G12C inhibitor D-1553, for the first time in cancer patients.

Nicox SA, an international ophthalmology company, announced that the results from its Dolomites Phase 2 clinical trial of NCX 470 in patients with open-angle glaucoma or ocular hypertension have been published online by the Journal of Glaucoma, the official journal of the World Glaucoma Association.

MTL-STING is the second drug candidate to be advanced from the Company’s internal pipeline of small activating RNA therapeutics STING is a highly validated drug target that plays a key role in immune evasion in cancer MiNA Therapeutics Limited, the pioneer in small activating RNA therapeutics, presents preclinical proof of mechanism data on MTL‑STING as a novel cancer immunotherapy.

Royal Philips, a global leader in health technology, and Oulu University Hospital announced a strategic 10-year partnership agreement to support the hospital’s ambitious OYS2030 renewal program.

Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of novel immunotherapies for difficult to treat solid cancers announced positive preclinical data on the treatment and analysis of the checkpoint resistant pancreatic syngeneic murine tumor model, Pan02.

Pfizer Inc. announced that David M. Denton will join the Company as Chief Financial Officer and Executive Vice President effective May 2, 2022.

Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced promising new in vivo and in vitro data that support the potential of the company’s novel gaseous nitric oxide (gNO) therapy to treat various types of solid tumors.